These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

787 related items for PubMed ID: 26893551

  • 1. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 8. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
    Saito T, Takeda A, Hashimoto K, Kobayashi A, Hayamizu T, Hagan GW.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun; 10():2393-404. PubMed ID: 26604737
    [Abstract] [Full Text] [Related]

  • 9. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, Amatto VC, Schmidt O, Bjermer L.
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [Abstract] [Full Text] [Related]

  • 10. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L.
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct; 10():1673-83. PubMed ID: 26316741
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
    Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, INSPIRE Investigators.
    Am J Respir Crit Care Med; 2008 Jan 01; 177(1):19-26. PubMed ID: 17916806
    [Abstract] [Full Text] [Related]

  • 15. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting.
    Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 01; 14():1441-1453. PubMed ID: 31308649
    [Abstract] [Full Text] [Related]

  • 16. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Jan 01; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 17. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.
    Ther Adv Respir Dis; 2018 Jan 01; 12():1753465818755091. PubMed ID: 29439648
    [Abstract] [Full Text] [Related]

  • 18. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A, Vilariño Pombo C.
    Arch Bronconeumol; 2005 Mar 01; 41(3):130-4. PubMed ID: 15766465
    [Abstract] [Full Text] [Related]

  • 19. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S.
    Drugs; 2016 Jan 01; 76(1):135-46. PubMed ID: 26683033
    [Abstract] [Full Text] [Related]

  • 20. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.
    Int J Chron Obstruct Pulmon Dis; 2014 Jan 01; 9():697-714. PubMed ID: 25045258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.